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Phase II Trials -endpoints, when to randomize Zee, Benny Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China The primary objective of phase II trials is to screen a new agent or regimen for efficacy and to provide estimates of its level of activity. In this workshop we will discuss commonly used endpoints such as complete plus partial response rate (overall response rate) and their corresponding analysis and interpretation. The use of multiple-stage design to minimize increase the efficiency of screening will be discussed. The importance in the design of phase II trials to minimize the chance that a truly active agent is erroneously rejected will also be discussed. There are circumstances that randomized phase II trial may be appropriate and its correct interpretation will be discussed.
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Designs with targeted therapies
West, Howard Swedish Cancer Institute, Seattle, WA, USA The study of targeted therapies in oncology requires consideration of several features that are unique to this class of agents. Trials of molecularly targeted therapies need to carefully assess whether it is appropriate to restrict the study of a targeted therapy to a population with a molecular variable that may be particularly relevant to a targeted therapy, or whether it is more appropriate to open the trial to a broader population that may experience a less consistent and robust improvement in clinical endpoints. Designs of trials with targeted therapies may also need to redefine the importance of such endpoints as maximum tolerated dose versus minimal effective dose, and of objective response versus disease control/non-progression. Trials designed as a "window of opportunity" allow for the rapid testing of a targeted therapy with a biological endpoint, while other trials with this design may incorporate novel endpoints such as metabolic imaging to assess results rapidly. Examples of clinical trials with targeted therapies in lung cancer also illustrate how early use of combinations of conventional chemotherapy and targeted therapy may obfuscate the contribution of the molecular therapy or may even produce antagonistic combinations, and of how a cross-over design may introduce new challenges in the interpretation of the contribution of a novel targeted therapy. Finally, multi-targeted single agents and combinations of different targeted therapies raise additional questions in clinical trial design of how to optimize efficacy, minimize safety risks, and evaluate the clinical benefit of regimens compared with traditional standards using more conventional agents.
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Novel clinical trial design applying Bayesian adaptive randomization for targeted therapy in lung cancer -A step toward personalized medicine
Lee, J. Jack Department of Biostatistics, M. D. Anderson Cancer Center, Houston, TX, USA Background: With the advancement in the understanding of multiple signaling pathways associated with lung cancer, many targeted therapies have been developed. Utilization of molecularly targeted agents can inhibit these specific aberrant pathways, hence, lead to clinical efficacy. The targeted agents, however, may not work for everyone. Biomarkers expressions can be used as indicators for the aberrant signaling to identify effective targeted therapy. Our major goals are to characterize the molecular signature of individual tumors, to offer bestfit targeted therapy to patients on the trial, and to identify promising targeted agents for future development.
Methods:
We have developed the "BATTLE" program, "Biomarkerintegrated Approaches of Targeted Therapy of Lung Cancer Elimination," which consists of an umbrella screening trial and 4 parallel phase II targeted therapies trials (with erlotinib, sorafenib, vandetanib, and the combination of erlotinib and bexarotene) in advanced non-small cell lung cancer patients with prior chemotherapy. All patients will have biopsy samples taken for biomarker profile assessment prior to the randomization, then they will be classified into one of the five marker groups: 1) EGFR mutation/amplification, 2) K-ras and/or B-raf mutation, 3) VEGF and/or VEGFR expression, 4) RXR and/or cyclin 
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D1 expression, and 5) none of the above. The primary endpoint of this study is disease control rate (DCR), which is defined as the fraction of patients who are in complete response, partial response, or stable disease state 8 weeks after randomization. The primary objective is to estimate and to test the DCR for each treatment arm given the patients' biomarker profiles. The null DCR and target DCR are set at 0.3 and 0.6, respectively. A total of 200 patients will be enrolled, stratified into one of the five marker groups, and then adaptively randomized into one of the four treatments. Design parameters were chosen to achieve 20% type I error and 90% power. The larger type I error rate was chosen to increase the power and to minimize the false negative rate in this phase II setting. We apply the outcome-based adaptive randomization to allocate patients into treatments based on ongoing and interim observed data. The Bayesian ordinal probit model (Albert J and Chib S. Bayesian analysis of binary and polychotomous response date, Journal of the American Statistical Association, 88, 669-679, 1993) is used to characterize the DCR. Gibbs sampling was applied to compute the posterior probabilities. Equal randomization will be performed for the first cohort of patients, until at least one patient's treatment outcome is available. Subsequently, the newly enrolled patients will be adaptively randomized to one of the four treatment arms according to their biomarker profile. The randomization rate is based on the updated posterior DCR from accumulated data in the trial. For each biomarker profile, better performing arms will have higher randomization rates and vise versa. Early stopping rules are set so that low-performing arms may be suspended for new patients being randomized into the arms . Results: Based on extensive simulation studies, the proposed design has the following desirable operating characteristics to: 1) recommend effective agents with high probability (80% for DCR=0.5 and 90% for DCR= 0.6); 2) recommend ineffective agents with low probability (<20% for DCR=0.3; 3) suspend ineffective agents with high probability (>60%); and 4) treat more patients with effective agents according to their biomarker profiles. The Bayesian design incorporates prior data and findings from the current patients to update estimates of the treatment efficacy for patients with different biomarker profiles. The design continues to "learn." The estimates continue to improve as the trial moves forward. The model-based method is useful in combining the information gathered from all 20 treatments by marker subgroups to make better inference. Discussion: The Bayesian AR design provides a smart and ethical design, which is ideally suitable for the development of targeted therapy. It can assist in identifying effective agents based on individual patients' tumor biomarker profile, thus providing the ability to treat more patients with effective therapies. Compared with the conventional approach, the Bayesian design can incorporate data from the literature and the interim results from the current trial to form better estimates of treatment efficacy for patients in different biomarker profiles. It is a "smart" design which matches patients with right drugs based on the up-to-date information. The information continues to be refined as the trial progresses. Important challenges remains to be addressed which include the following: 1) Prior specifications: The choice on how strong the prior should be to incorporate the prior information and allowing borrowing strength across treatment and biomarker subgroups; 2) Adaptive randomization ratio: Patients with different biomarker profile are adaptively randomly assigned to treatments based on the posterior mean of the marginal DCRs.
It is an open question on how much weight should be given to the posterior DCR; 3) Biased in estimating the population DCR. Adaptive randomization can cause bias in estima-tion due to dependent sampling scheme. It is important to quantify and correct the bias; 4) Specification on the early stopping rule. Stopping to randomize patients into ineffective treatments is desirable but stopping too early may result in false negative conclusion; 5) Missing biomarker information. In clinical settings, not every patient has a biopsiable tumor. In addition, an assessment of the entire biomarker panel may not be complete for some patients. Shall patients with no or partial biomarker results be enrolled in the study? If so, how? 6) Biomarker assessment, outcome evaluation, and accrual. To apply the biomarker driven, outcome based adaptive randomization; the time for biomarker assessment needs to be short. The time for outcome evaluation needs to be relatively short and the accrual cannot be too fast as well, so that the decision based on up-to-date data can provide appropriate guidance for subsequent patients; 7) Trial conduct. We have developed a database to capture the biomarker and outcome information in real time. Bayesian computation and the randomization algorithm were written in R. An integrated web-base application was built via web services.
In the midst of many challenges, we have derived an adaptive randomization design to achieve our goals of identifying the effective agents for patients with different biomarker profiles and better treating patients on the trial. It is a step towards "personalized medicine." With the growing medical knowledge and molecular/genomic biomarker tools, an efficient and flexible design, such as this, will enable us continue to learn more about the new agents' clinical activities and their molecular underpinning in real time. Applying this knowledge, we will be able to provide better treatments to current and new patients.
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